# TEXAS HEALTH AND HUMAN SERVICES COMMISSION RATE ANALYSIS DEPARTMENT

Proposed Medicaid Payment Rates for Physician-Administered Drugs – Kadcyla (J9354)

Payment rates are proposed to be effective July 1, 2014

#### SUMMARY OF PROPOSED MEDICAID PAYMENT RATES

# Effective July 1, 2014

Included in this document is information relating to the proposed Medicaid payment rates for Physician-Administered Drugs – Kadcyla (J9354). The rates are proposed to be effective July 1, 2014

### Hearing

The Health and Human Services Commission (HHSC) will conduct a public hearing to receive comments regarding the proposed Medicaid rates detailed in this document on August 21, 2014, at 1:30 p.m. in the Public Hearing Room in the Brown-Heatly Building at 4900 North Lamar Boulevard, Austin, Texas 78751, with entrance through Security at the front of the building facing Lamar Boulevard. HHSC will consider concerns expressed at the hearing prior to final rate approval. This public hearing is held in compliance with the provisions of Human Resources Code §32.0282 and the Texas Administrative Code, Title 1 (1 TAC), §355.201, which require a public hearing on proposed payment rates. Should you have any questions regarding the information in this document, please contact:

Rozsalind Brown, Acute Care Rate Analysis
Texas Health and Human Services Commission
(512) 730-7462; FAX: (512) 730-7475
E-mail: rozsalind.brown@hhsc.state.tx.us

HHSC also will broadcast the public hearing; the broadcast can be accessed at <a href="http://www.hhsc.state.tx.us/news/meetings.asp">http://www.hhsc.state.tx.us/news/meetings.asp</a>. The broadcast will be archived and can be accessed on demand at the same website.

## Background

HHSC is responsible for the reimbursement determination functions for the Texas Medicaid Program. Proposed rates are calculated utilizing established methodologies that conform to the Social Security Act and related federal regulations, the federally approved Texas Medicaid State Plan, all applicable state statutes and rules, and other requirements. HHSC reviews the Medicaid reimbursement rates for all acute care services every two years. These biennial reviews result in rates that are increased, decreased, or remain the same. The reviews are conducted to ensure that rates continue to be based on established rate methodologies.

#### Methodology

The specific administrative rules that govern the establishment of the fees in this proposal include these rules in 1 TAC:

- §355.8085, which addresses the reimbursement methodology for physicians and other practitioners; and
- §355.8441, which addresses the reimbursement methodology for Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) services.

### **Proposed Rates**

Procedure codes and descriptions used in the Texas Medicaid Program are national standard code sets as required by federal laws; Healthcare Common Procedural Coding System (HCPCS) and Current Procedural Terminology (CPT). The proposed rates are based on 89.5 percent of the Average Wholesale Price of the drug.

Proposed payment rates are listed in the attachment outlined below:

Attachment – Physician-Administered Drugs – Kadcyla (J9354)